We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.
- Authors
Lee, Dong-Hee; Jeong, Yu-Jeong; Won, Ju-Young; Sim, Hye-In; Park, Yoon; Jin, Hyung-Seung
- Abstract
Immune checkpoint inhibitor therapy has proven efficacy in a subset of colon cancer patients featuring a deficient DNA mismatch repair system or a high microsatellite instability profile. However, there is high demand for more effective biomarkers to expand the colon cancer population responding to ICI therapy. PBK/TOPK, a serine/threonine kinase, plays a role in cell cycle regulation and mitotic progression. Here, we investigated the correlation between PBK/TOPK expression and tumor immunity and its prognostic value in colon cancer. Based on large-scale bioinformatics analysis, we discovered that elevated PBK/TOPK expression predicted a favorable outcome in patients with colon cancer and was positively associated with immune infiltration levels of CD8+ T cells, CD4+ T cells, natural killer cells, and M1 macrophages. In contrast, a negative correlation was found between PBK/TOPK expression and immune suppressor cells, including regulatory T cells and M2 macrophages. Furthermore, the expression of PBK/TOPK was correlated with the expression of T-cell cytotoxicity genes in colon cancer. Additionally, high PBK/TOPK expression was associated with mutations in DNA damage repair genes, and thus with increased tumor mutation and neoantigen burden. These findings suggest that PBK/TOPK may serve as a prognostic and predictive biomarker for immunotherapy in colon cancer.
- Subjects
COLON cancer; KILLER cells; DNA mismatch repair; REGULATORY T cells; SUPPRESSOR cells; HEREDITARY nonpolyposis colorectal cancer; SERINE/THREONINE kinases; IPILIMUMAB
- Publication
Biomedicines, 2022, Vol 10, Issue 2, p299
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines10020299